Elan/Amarin Zelapar NDA accepted
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryFDA accepts Elan's NDA filing for Zelapar, a fast-dissolving tablet formulation of the MAO-B inhibitor selegiline. Generically available selegiline is approved as adjunct treatment to levodopa for the symptoms of Parkinson's disease. The fast-dissolving formulation is intended to address the difficulty in swallowing Parkinson's patients may experience. Amarin has an option for U.S. right
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.